Publications by authors named "S Pulizzi"
Background: This meta-analysis compared the diagnostic performance of [F] fluorodeoxyglucose ([F]FDG) positron emission tomography/computed tomography (PET/CT) or PET versus Magnetic resonance imaging (MRI) in detecting recurrence or residual tumors at the primary site in patients with nasopharyngeal carcinoma (NPC).
Methods: A comprehensive literature search was conducted in the PubMed/MEDLINE and CENTRAL databases to find studies with at least 20 patients with NPC undergoing both [F]FDG PET/CT (or [F]FDG PET) and MRI for detecting recurrence or assessing residual disease at the primary site. The pooled sensitivity and specificity of PET/CT and MRI were calculated with 95% confidence intervals (CIs) and compared.
CAR-T-cell therapy, also referred to as chimeric antigen receptor T-cell therapy, is a novel method in the field of immunotherapy for the treatment of non-Hodgkin's lymphoma (NHL). In patients receiving CAR-T-cell therapy, fluorodeoxyglucose Positron Emission Tomography/Computer Tomography ([F]FDG PET/CT) plays a critical role in tracking treatment response and evaluating the immunotherapy's overall efficacy. The aim of this study is to provide a systematic review of the literature on the studies aiming to assess and predict toxicity by means of [F]FDG PET/CT in patients with NHL receiving CAR-T-cell therapy.
View Article and Find Full Text PDFThe aim of this study was to investigate whether high body mass index (BMI) increases the risk of recurrence and correlates with higher glucose uptake in recurrent lesions in post-menopausal female patients with breast cancer. A hospital database was searched to retrieve breast cancer patients who had undergone an [F]FDG PET/CT scan before neoadjuvant chemotherapy and curative-intent surgery. BMI was calculated at the baseline [F]FDG PET/CT scan.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how baseline [F]FDG-PET/CT scans can predict the effectiveness of immunotherapy and overall survival in lung cancer (LC) and malignant melanoma (MM) patients.
- Conducted over several months in 2021, the study included 278 patients who underwent PET/CT scans shortly before starting treatment and were monitored for at least a year.
- Results showed that in lung cancer patients, higher [F]FDG uptake often indicated a lack of response to therapy, while there was only a weak link between PET/CT findings and therapy outcomes in melanoma patients.
Aim: To examine the role of [18F]FDG PET/CT for assessing response to immunotherapy in patients with some solid tumors.
Methods: Data recorded in a multicenter ( = 17), retrospective database between March and November 2021 were analyzed. The sample included patients with a confirmed diagnosis of a solid tumor who underwent serial [18F]FDG PET/CT (before and after one or more cycles of immunotherapy), who were >18 years of age, and had a follow-up of at least 12 months after their first PET/CT scan.